This highlights the importance of (1) better understanding the frequency of endorsement of SCD features in individuals with preclinical AD pathological changes, and also of (2) identifying the features of SCD that are most sensitive to either Aβ and tau levels when the biomarker status is unknown, in order to improve clinical trial inclusion criteria. This evidence concerns the gene MAPT and Schnyder corneal dystrophy.